Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096226 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00096226 is a Phase 2 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 60 participants.
The verdict
NCT00096226, a Phase 2 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving paclitaxel and carboplatin together with radiation therapy before surgery may shrink the tumor so that it can be removed. Giving chemotherapy after surgery may kill any tumor cells remaining after surgery. PURPOSE: This phase II trial is studying how well giving paclitaxel and carboplatin together with radiation therapy works in treating patients who are undergoing surgery for stage III non-small cell lung cancer.
Interventions
- RADIATION Radiation Therapy
- PROCEDURE Resection
- DRUG Induction Carboplatin
- DRUG Induction Paclitaxel
- DRUG Consolidation Carboplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2004-09 |
| Est. Completion | 2016-05-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00096226
The ClinicalTrials.gov registry entry for NCT00096226 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Radiation Therapy is the first listed.
NCT00096226 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00096226 about?
NCT00096226 is a clinical study titled "Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving paclitaxel and carboplatin together with radiation therapy before s...
What is the current status of trial NCT00096226?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2004-09. Estimated completion is 2016-05-16.
What interventions are being tested in trial NCT00096226?
The interventions under investigation include: Radiation Therapy (RADIATION), Resection (PROCEDURE), Induction Carboplatin (DRUG), Induction Paclitaxel (DRUG), Consolidation Carboplatin (DRUG).
Who is sponsoring clinical trial NCT00096226?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.